Intellectual property and COVID-19 medicines: why a WTO waiver may not be enough

By Enrico Bonadio, Reader in Intellectual Property Law, City, University of London
Dhanay M. Cadillo Chandler, Postdoctoral research fellow, University of Turku

The COVID-19 pandemic, and the race to make vaccines and other useful technologies more accessible to people around the world, has once again highlighted the tension between intellectual property rights and the promotion of public health.

There is no doubt that the monopolies offered by exclusive rights such as patents are necessary to incentivise pharmaceutical companies to invest huge resources and develop useful drugs. These rights help manufacturers…

Read complete article

~	How visas for social care workers may be exacerbating exploitation in the sector

~	Why the British Columbia Conservation Officer Service should be designated as a provincial police service

~	Detaining migrants in prisons violates human rights and risks abuses

~	Granting legal ‘personhood’ to nature is a growing movement – can it stem biodiversity loss?

~	Friday essay: Project 2025, the policy substance behind Trump’s showmanship, reveals a radical plan to reshape the world

~	Longer-lasting ozone holes over Antarctica expose seal pups and penguin chicks to much more UV

~	New rock art discoveries in Eastern Sudan tell a tale of ancient cattle, the ‘green Sahara’ and climate catastrophe

~	Will checking character references really help you find the best candidate for a job?

~	China’s money only goes so far – Kokoda shows why history binds PNG and Australia in a far deeper way

~	We spoke to young people about sexual consent. They understand the concept, but don’t always ask in the moment